ViaLase, Inc., a clinical-stage medical technology company focused on addressing unmet needs in the conventional glaucoma treatment paradigm, today announced it has completed enrollment of VIA-002, the company’s pivotal trial of the ViaLase® Laser to treat adult patients with primary open angle glaucoma (POAG).
